Rutgers, The State University

Rutgers, The State University, doing business as Rbhs-New Jersey Medical School, is a non-profit 1862 land grant college operating as a subsidiary of Rutgers University that serves as a prime recipient on federal medical research contracts and grants, performing genomics sequencing, medical imaging research, and infectious disease therapeutic development for the Department of Veterans Affairs and the National Institutes of Health with no set-aside category designation across its federal footprint.

The New Jersey Medical School operates from Newark, New Jersey with clinical and research operations at multiple locations including East Orange and Allegheny-West, Pennsylvania. Rutgers competes full-and-open in all recent work; the vendor carries no SBA certifications and does not pursue or hold set-aside vehicles. The university's federal contracting footprint spans 352 awards (95% prime, 5% sub) across 39 customer agencies with combined potential value of $168.8 million and obligated dollars of $584.1 million. Recent award activity has moderated from nine awards in 2022 to three in each of 2025 and 2026.

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) dominates the award portfolio, representing 81 awards and $107.3 million in combined potential value. The Department of Veterans Affairs Veterans Integrated Service Network 2 ranks second with 25 awards and $58.4 million, reflecting a heavy concentration in VA medical services and research. The remainder of the top five customers — the broader National Institutes of Health, HHS, and the National Heart Lung and Blood Institute — collectively anchor a 64% coverage of award count. This concentration underscores Rutgers' role as a leading recipient on biomedical and infectious disease research grants from NIH subdivisions and a provider of specialized medical services to VA networks.

Recent representative prime work includes a $44.5 million ten-year definitive contract with VA Veterans Integrated Service Network 2 (awarded August 1, 2024, through July 31, 2034) for vascular surgical services at East Orange, New Jersey; a $1.3 million single-award indefinite delivery contract with VA Veterans Integrated Service Network 2 (September 1, 2026, through February 29, 2032) for genomics center RNA sequencing services in Newark; and a $97,585 delivery order with VA Veterans Integrated Service Network 4 (August 27, 2025, through August 26, 2026) for collaborative biplanar fluoroscopy research to study bone and skin movement in individuals with transtibial amputations. The university also holds a large IDV from NIAID with reported potential value exceeding $100 million for preclinical development support on HIV, hepatitis, and tuberculosis candidate products. Federal grant work includes a National Institute of Neurological Disorders and Stroke project grant (April 2022 through April 2023) on the role of TRPM3 ion channels in opioid-induced analgesia and pruritus, and a Defense Health Agency project grant (January 2022 through January 2026) on type I and type III interferons in malaria pre-erythrocytic immunity.

Rutgers appears on parent contracts and vehicles that support medical research delivery orders. The top vehicles by task-order count include four delivery orders under an IDC for biomedical research support and four under a VA indefinite delivery contract for imaging and genomics services. A minor recompete cliff of $47 thousand is due within the next twenty-four months.

As a sub-recipient, Rutgers performs research under grants led by Weill Medical College of Cornell University (tuberculosis immunology, HPV vaccine trials, oxidative stress in neuronal cells), the University of Washington (tuberculosis genetics and drug resistance), Johns Hopkins University (tuberculous meningitis preclinical modeling), Michigan State University (bacterial cytidine deaminase biochemistry), and Henry Ford Health System (alcohol use following bariatric surgery). The university's federal grant footprint reflects specialization in infectious disease immunology, neuroscience, and translational medical research across NIH institutes and the Defense Health Agency.